Mesoblast Ltd.

Mesoblast Ltd. Sponsored ADR represents shares in Mesoblast Limited, an Australian biopharmaceutical company focused on developing innovative cellular medicines. The company’s primary aim is to address complex medical conditions involving significant inflammation and tissue damage by leveraging its world-leading mesenchymal lineage cell therapy platform. Mesoblast's research predominantly targets large and unmet medical needs in fields such as cardiovascular, orthopedic, and hematological diseases. The company's advanced cell therapies are at the forefront of regenerative medicine, with promising treatments aimed at conditions such as chronic heart failure, back pain due to degenerative disc disease, and graft versus host disease. By providing American investors access to Mesoblast shares through the American Depositary Receipt system, this asset facilitates diversified participation within the dynamic biopharmaceutical landscape. The ADRs trade on U.S. exchanges, broadening the company's investor base beyond its Australian origins and integrating with the international financial markets, playing a vital role in the translation of advanced medical research into viable treatments with global implications.